ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

EFFICACY AND SAFETY SUPPORTED BY UP TO 6.5 YEARS’ CUMULATIVE CLINICAL TRIAL EXPERIENCE⁴
in patients with haemophilia B⁴

In a longitudinal post hoc analysis of pivotal trial data (N=120), ALPROLIX:⁴

Maintained low ABRs^4,5

ABRs remained low across all age groups on prophylaxis^4,5

Median ABR for patients on weekly prophylaxis
treatment during B-LONG and B-YOND⁵

Resolved target joints⁴

A sub-analysis showed:

100% (93/93)

of target joints in 37 patients
resolved during treatment⁴

No recurrence in 90% (83/93) of target joints during follow-up⁴

Achieved high adherence⁴

Dose adherence on weekly or individualised prophylaxis

B-LONG

Kids B-LONG

*Outcome measures included the cumulative duration of ALPROLIX, number of exposure days, longitudinal overall ABR, annualised joint bleed rate (AjBR), annualised spontaneous bleed rate, annualised traumatic bleed rate, and the consumption of ALPROLIX (total IU/kg per subject per year).⁴
ABR, annualised bleeding rate; IQR, interquartile range.

ALPROLIX was well tolerated in the Phase 3 clinical trials,
reinforcing an established safety profile⁴

No inhibitor development, anaphylaxis or
serious hypersensitivity, or vascular thrombotic
events during long-term treatment⁴

No new safety signals or concerns emerged
during long-term follow-up on extended dosing*⁴

*Reported for sub-group analysis of patients on extended dosing intervals (>14 days).⁴

A post hoc efficacy and safety analysis of pooled longitudinal data from
patients previously enrolled in pivotal trials*⁴

*In the Phase 3 trials, 123 and 30 patients were enrolled in B-LONG and Kids B-LONG respectively.⁴